Rivera-Munoz E Andres, Zhao Xiaonan E, Rosenfeld Jill A, Luna Pamela N, Shaw Chad A, Posey Jennifer E, Scott Daryl A
Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, USA.
Genetics and Genomics Graduate Program, Baylor College of Medicine, Houston, TX, USA.
Eur J Hum Genet. 2025 Sep 6. doi: 10.1038/s41431-025-01929-3.
Congenital Anomalies of Kidney and Urinary Tract (CAKUT) can occur in isolation or in conjunction with one or more non-CAKUT associated congenital anomalies or neurodevelopmental disorders (CAKUT+). A molecular cause is not identified in most individuals with CAKUT+. This is due, in part, to uncertainty regarding the efficacy of genetic testing and an incomplete understanding of the genes that cause CAKUT+. Here, we use data from 515 individuals with CAKUT+ (n = 500) or isolated CAKUT (n = 15) to determine the efficacy of clinical exome sequencing (cES) and to identify new phenotype expansions that involve CAKUT. We determined that cES established a molecular diagnosis in 27.4% (141/515) of individuals in this cohort. No statistically significant difference in efficacy was seen with regards to age, sex, CAKUT phenotype, or associated organ system abnormality. Only 3.5% (5/144) to 14.6% (21/144) of the individual diagnoses made in our cohort could have been identified using one of four clinically available CAKUT gene panels. We then used a machine-learning approach to confirm that PHIP is a CAKUT gene and to implicate ADNP and SETD5 genes associated with an increased risk of CAKUT. These findings lead us to conclude that cES should be considered in individuals with CAKUT+ for whom a molecular diagnosis has not been identified, that cES has the potential to identify many diagnoses in individuals with CAKUT+ that would be missed using a CAKUT gene panel, and that individuals with ADNP-, PHIP-, and SETD5-related disorders may present with CAKUT phenotypes.
先天性肾脏和尿路畸形(CAKUT)可单独出现,或与一种或多种非CAKUT相关的先天性畸形或神经发育障碍(CAKUT+)同时出现。大多数CAKUT+个体的分子病因尚未明确。部分原因是基因检测的有效性存在不确定性,以及对导致CAKUT+的基因理解不完整。在此,我们使用来自515名CAKUT+个体(n = 500)或孤立性CAKUT个体(n = 15)的数据,以确定临床外显子组测序(cES)的有效性,并识别涉及CAKUT的新的表型扩展。我们确定cES在该队列中27.4%(141/515)的个体中确立了分子诊断。在年龄、性别、CAKUT表型或相关器官系统异常方面,未观察到有效性的统计学显著差异。使用四个临床可用的CAKUT基因panel之一,本队列中仅3.5%(5/144)至14.6%(21/144)的个体诊断可以被识别。然后,我们使用机器学习方法确认PHIP是一个CAKUT基因,并暗示ADNP和SETD5基因与CAKUT风险增加相关。这些发现使我们得出结论,对于尚未确定分子诊断的CAKUT+个体,应考虑进行cES,cES有潜力识别许多CAKUT+个体中使用CAKUT基因panel会遗漏的诊断,并且患有ADNP、PHIP和SETD5相关疾病的个体可能表现出CAKUT表型。